BRNS (Barinthus Biotherapeutics) Short-Term Debt to Capital
Barinthus Biotherapeutics (BRNS) laboratories are currently focused on conducting clinical trials using calibrated equipment and reserved partner capacities. This chart of the market trend in monetary terms shows a debt-to-equity ratio of 0.05, while the business implements energy-saving technologies to minimize its environmental footprint. High barriers to entry are ensured by patents for cancer and hepatitis B therapies under strict FDA and EMA supervision.
Analytical breakdowns for Barinthus Biotherapeutics
- stock quotes and analyst forecast:
- business market valuation indicators:
- book capitalization information:
- company liabilities and liquidity data:
Total Debt to Capital Barinthus Biotherapeutics|BRNS - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Barinthus Biotherapeutics plc|BRNS - Aggregate Debt Obligations|Debts to Book Capitalization Barinthus Biotherapeutics PLC|BRNS - Long-Term Debt Volume|Company Short-Term Debt Barinthus Biotherapeutics|Quick Liquidity barinthusbio.com
- company profitability and valuation multiples indicators:
Fundamental valuation:Barinthus Bio
This indicator compares liabilities with a maturity of up to one year against net assets, measuring the company's dependence on short-term borrowing. For Barinthus Biotherapeutics (BRNS), which possesses significant pricing power in the immunotherapy segment, analyzing the short-term financial leverage ratio on GURU.Markets allows for an assessment of how effectively the unique ChAdOx platform generates liquidity to service current debts without the risk of capital freezing.
Main competitors
Short-Term Debt to Capital ARGX|BNTX (BioNTech Pharma) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ABVX (Abivax Pharma)|Short-Term Debt to Capital admabiologics.com ADMA|PTGX - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital IMVT (Immunovant Inc)|Kiniksa Pharmaceuticals Ltd (KNSA) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Grifols Biemat|ADPT (Adaptive Biotechnologies) - Short-Term Debt to Capital|Short-Term Debt to Capital celldex.com|Short-Term Debt to Equity Ratio AUPH (Aurinia Pharmaceuticals Inc.)|BCRX (BioCryst Pharmaceuticals, Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital VERA (Vera Pharma)|Short-Term Debt to Capital Coefficient Dianthus Corp (DNTH)|PHVS - Short-Term Debt to Equity|AbCellera Biologics Inc (ABCL) - Short-Term Debt to Equity Ratio|Tourmaline Bio (TRML) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Precigen Inc|Short-Term Debt to Equity Ratio PHAR|Short-Term Debt to Capital Nektar Corp|Short-Term Debt to Equity Upstream Bio Inc (UPB)|zenasbio.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital IMNM (Immunome)|Gossamer Bio Inc (GOSS) - Current Liabilities to Capital|KalVista Pharmaceuticals Inc - Short-Term Debt to Capital|SEPN: Short-Term Debt to Equity|PVLA: Short-Term Debt to Capital|savarapharma.com (SVRA) - Short-Term Debt to Capital|Short-Term Debt to Equity Rigel Pharmaceuticals, Inc.|ANAB: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ATXS|Short-Term Debt to Capital Coefficient enGene Corp|Short-Term Debt to Equity RAPT Therapeutics RAPT|JBIO: Short-Term Debt to Capital Ratio|ACRS: Short-Term Debt to Equity Ratio|Kyverna Therapeutics Inc. - Short-Term Loans to Capital Ratio|TLSA: Short-Term Debt to Capital|Cabaletta Bio Inc - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio VTYX|Short-Term Debt to Capital theratech.com|Short-Term Debt to Equity Avalo Therapeutics (AVTX)|Short-Term Debt to Capital Coefficient Eledon Pharmaceuticals Inc.|Agenus Inc - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital CLYM|Zura Bio - Short-Term Debt to Capital|ATYR: Short-Term Debt to Equity|ADAG: Short-Term Debt to Capital|IMA - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Shattuck Labs Inc|Current Liabilities to Capital Equillium Bio EQ|Short-Term Debt to Equity Ratio CNTB (Connect Biopharma)|Short-Term Loans to Capital Ratio IMUX|Short-Term Debt to Capital ATRA (Atara Bio)|Ratio of Short-Term Indebtedness to Capital IFRX|X4 Pharma - Short-Term Debt to Capital|Current Liabilities to Capital Adicet Bio|celularity.com (CELU) - Short-Term Debt to Equity|inmunebio.com - Ratio of Short-Term Indebtedness to Capital|KZR (Kezar Life Sciences, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital SAB Biotherapeutics Inc.|Short-Term Debt to Equity Akari Therapeutics plc (AKTX)|ENLV: Current Liabilities to Equity|Short-Term Debt to Capital QTTB (Q32 Bio)|geovax.com (GOVX) - Current Liabilities to Capital|EDSA: Short-Term Debt to Equity Ratio|IBIO - Short-Term Debt to Capital|CARM (carismatx.com) - Short-Term Debt to Equity Ratio|XTLB: Short-Term Loans to Capital Ratio|BOLT (Bolt Biotherapeutics Inc.) - Short-Term Debt to Capital|HCW Biologics Inc (HCWB) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital APVO|Short-Term Debt to Equity Ratio aimimmuno.com AIM|Short-Term Debt to Equity Aditxt, Inc. ADTX|Short-Term Debt to Capital Coefficient GRI Bio Corporation (GRI)|XORTX Therapeutics Inc. - Short-Term Debt to Capital|HIND: Short-Term Debt to Equity|Revelation Biosciences, Inc. (REVB) - Short-Term Debt to Equity|Indaptus Therapeutics Inc - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Scinai|Short-Term Debt to Capital Ratio CALI (CalciMedica Corp)|Short-Term Debt to Equity Affimed (AFMD)|Short-Term Debt to Capital Coefficient allakos.com|Short-Term Debt to Equity HOOKIPA Pharma HOOK|IGMS (IGM Biosciences Inc.) - Current Liabilities to Equity|iTeos - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital OCEA (Ocean Biomedical Corp)|TCBP: Short-Term Debt to Capital|thirdharmonicbio.com (THRD) - Short-Term Debt to Capital